BioClonal
A team, a lab focused
On developing solutions against peptides the way to fight Alzheimer
Founded to overcome one of the greatest challenges in modern biomedicine — developing antibodies against highly complex biological targets involved in diseases that still lack effective solutions.
CORE FOCUS
Founded exclusively to overcome standard immunization limits against challenging peptide epitopes.
KEY INNOVATION
Superimmunogen design systematically converts low-immunogenic peptides into reliable targets.
VALUE STREAMS
A diversified biotech model spanning Custom Services, Catalog, and Proprietary Clinical R&D.
our story
Every three seconds, someone in the world develops dementia. Behind every Alzheimer’s diagnosis is a person, a family, and a future changed forever as memories fade, identities become blurred, and independence is gradually lost.
At BioClonal, we believe science can change this reality.
Our company was founded with a clear ambition: to overcome one of the greatest challenges in modern biomedicine—the discovery of antibodies against highly complex biological targets, many of which are involved in diseases that still lack effective therapeutic solutions.
Our company was founded with a clear ambition: to overcome one of the greatest challenges in modern biomedicine—the discovery of antibodies against highly complex biological targets, many of which are involved in diseases that still lack effective therapeutic solutions.
Today, our primary focus is Alzheimer’s disease. We are advancing novel antibody-based approaches to address biological mechanisms that remain insufficiently explored, with the ultimate goal of contributing to a future where Alzheimer’s can be prevented, better diagnosed, and effectively treated.
Who we are
BioClonal is a biotechnology company founded in 2022 with a mission to develop innovative antibody-based therapies for Alzheimer’s disease. Our proprietary platform enables the generation of immune responses against highly challenging biological targets, expanding the possibilities for discovering therapies where conventional approaches often fall short.
We combine a differentiated technology platform with a clear purpose: to help preserve what makes us human—our memories, our identity, and our connection to the people we love.
Olga Julián
Chief Financial Officer (CFO)
Paula Garfella
Chief Executive Officer (CEO)
Javier Garfella
Chief Scientific Officer (CSO)
Marina Pardo
Research Scientist
Andrea Segovia
R&D Technician
OBSESSION
Our
values
Patients First
Everything we do is driven by a single purpose: improving the lives of people affected by neurodegenerative diseases.
Science with Impact
We pursue scientific breakthroughs not only to expand knowledge, but to create meaningful solutions for patients and society.
Courage to Tackle Complexity
We focus on the most challenging biological problems because solving them can deliver the greatest benefit to patients.
Scientific Excellence
Innovation requires rigor, curiosity, integrity, and an unwavering commitment to quality.
Collaboration
We believe that meaningful progress against Alzheimer’s can only be achieved through collaboration among researchers, clinicians, industry partners, and patient communities.
Who we work with
From pharma and biotech companies to CROs and academic research groups, BioClonal partners with organizations that need reliable antibody solutions for the most challenging peptide targets.
Pharma
/Biotech
NEED
Antibodies for difficult targets
BIOCLONAL SOLUTION
Custom development
CROs
NEED
Outsourcing complex projects
BIOCLONAL SOLUTION
Technical collaboration
Academia
NEED
Use of validated antibodies
BIOCLONAL SOLUTION
Ready-to-use
Diagnostics
NEED
Use of validated antibodies
BIOCLONAL SOLUTION
Ready-to-use
Investors
NEED
High-potential pipeline
BIOCLONAL SOLUTION
Alzheimer Program
Because every
memory matters
At BioClonal, we are working to turn scientific innovation into new hope for patients and families affected by Alzheimer’s disease.
Our three pillars.
Our specialized technology enables the generation of antibodies against challenging targets that are not accessible using conventional approaches.
Custom Peptide Antibody Development
BioClonal provides custom antibody development services focused on peptide-based targets across therapeutic areas.
«WE GENERATE ANTIBODIES WHEN OTHERS FAIL»
Alzheimer
Antibody Catalog
Our catalog is specifically designed around peptide targets involved in Alzheimer’s disease, including Tau and Amyloid-beta related epitopes.
FOR ALZHEIMER RESEARCH»
Proprietary R&D
Our catalog is specifically designed around peptide targets involved in Alzheimer’s disease, including Tau and Amyloid-beta related epitopes.
«ADVANCING A NOVEL THERAPEUTIC ANTIBODY«
your project